Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well gemcitabine hydrochloride works with or
without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma.
Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by
blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is
more effective with or without pazopanib hydrochloride in treating patients with soft tissue
sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals Oregon Health and Science University